LABP
- Landos Biopharma, Inc.
()
Overview
Company Summary
Landos Biopharma, Inc. (LABP) is a biotechnology company that focuses on the development and commercialization of novel, orally administered therapeutics for autoimmune diseases. The company's primary objective is to discover and develop medications that target the underlying cause of autoimmune disorders, rather than treating the symptoms alone.
LABP utilizes its proprietary platform, called LANCE (LANd-Enabled Oral biologics), which combines artificial intelligence (AI) and data-driven approaches to identify and design therapeutic candidates that can selectively modulate the gut-sparing pathway. The gut-sparing pathway refers to a targeted approach that minimizes the systemic immune suppression associated with current treatments for autoimmune diseases.
The company's investigational drugs aim to restore normal function and balance to the immune system. By specifically targeting the gut mucosa, Landos Biopharma aims to minimize systemic side effects while effectively treating autoimmune diseases, providing potential benefits to patients in terms of reduced side effects and improved long-term outcomes.
Landos Biopharma's pipeline includes various candidates targeting specific autoimmune disorders like ulcerative colitis, Crohn's disease, and autoimmune hepatitis, among others. The company is actively engaged in clinical trials to evaluate the safety and efficacy of these potential therapies.
Overall, Landos Biopharma is advancing the development of innovative oral therapeutics that have the potential to transform the treatment landscape for autoimmune diseases and improve the quality of life for patients suffering from these conditions.